In a landmark decision, the Circuit Court of Cook County in Chicago has found Johnson & Johnson (NYSE: JNJ) and two of its subsidiaries, Johnson & Johnson Holdco, Inc., and Kenvue, Inc. (NYSE: KVUE), liable for the asbestos-related death of Theresa Garcia, a mother and grandmother. The family was awarded $45 million in damages, concluding […]
Ikena Oncology has secured fast track designation for IK-930 from the US Food and Drug Administration in the treatment of unresectable NF2-deficient malignant pleural mesothelioma. IK-930 is a TEAD inhibitor designed to target the Hippo signaling pathway. Earlier this year, IK-930 was granted the FDA orphan drug designation for the treatment of patients having malignant […]
TCR2 Therapeutics has reported positive interim results from its phase 1 part of the phase 1/2 clinical trial of its T-cell therapy candidate gavo-cel in mesothelin-expressing solid tumors. The US-based clinical-stage cell therapy company said that as of the 30 June 2021 data cutoff, 17 patients, which include 12 mesothelioma, four ovarian cancer and one […]
Cadila Healthcare (also known as Zydus Cadila) said that it has secured tentative approval from the US Food and Drug Administration (FDA) for marketing Pemetrexed for Injection in 100mg/vial, 500mg/vial, and 1000mg/vial, single-dose vials. Pemetrexed for Injection is the generic for Eli Lilly and Company (Lilly) owned Pemetrexed, which is sold under Alimta and other […]